Expertise in
11
conditions

Flavio R. Sztajnbok

Br, 
Rio De Janeiro, RJ, BR 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
11
conditions
Br, 
Rio De Janeiro, RJ, BR 

Overview

Flavio Sztajnbok practices practicing medicine in Rio De Janeiro, Brazil.

Mr. Sztajnbok is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Scleroderma, Systemic Sclerosis (SSc), Juvenile Idiopathic Arthritis (JIA), and Systemic Lupus Erythematosus (SLE).

He is actively involved in clinical research, co-authoring 78 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Br, Rio De Janeiro, RJ, Brazil

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: May 12, 2026
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3

78 Total Publications

What is the treatment pattern of juvenile systemic sclerosis? Results from an international cohort.
What is the treatment pattern of juvenile systemic sclerosis? Results from an international cohort.
Journal: Journal of scleroderma and related disorders
Published: April 15, 2026

Frequently Asked Questions about Flavio R. Sztajnbok

Is Flavio R. Sztajnbok a top-rated expert for Scleroderma?

MediFind is an objective health platform that identifies experts based on real-world data. Flavio R. Sztajnbok is classified as an Distinguished expert for Scleroderma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Flavio R. Sztajnbok participate in research or clinical trials?

Yes. Flavio R. Sztajnbok has published 78 articles and abstracts on conditions like Scleroderma. You can view a list of Flavio R. Sztajnbok's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Sztajnbok's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 31 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile